{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123255","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.241980+00:00","generated_at":"2026-05-30T03:38:39.486950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024","bullets":["Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.","Cash, equivalents and investments $342.6M as of Sept 30, 2024; projected runway into 2H 2027.","Initiation of pivotal Phase 3 CIDP trial (single, two-part, randomized withdrawal) expected by year-end 2024.","Phase 2 MaGic gMG trial on track for top-line data 2H 2025; Phase 2 MoMeNtum MMN trial for 2H 2026.","Steven Romano, M.D., appointed to board effective Sept 16, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123255","json":"https://secwatch.observer/filing/0000950170-24-123255.json","markdown":"https://secwatch.observer/filing/0000950170-24-123255.md","text":"https://secwatch.observer/filing/0000950170-24-123255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/0000950170-24-123255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:38:39.486950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}